Inovio Pharmaceuticals, Inc. - Common Stock (INO)

Inovio Pharmaceuticals (NASDAQ:INO) said the U.S. Food and Drug Administration granted accelerated approval to VOCERYQ, formerly known as INO-3107, as a nonsurgical treatment intended to reduce the frequency of surgeries in adults with recurrent respiratory papillomatosis, or RRP. VOCERYQ is the co

Inovio Pharmaceuticals (NASDAQ:INO) said its biologics license application for INO-3107, an investigational DNA medicine for recurrent respiratory papillomatosis, or RRP, remains under U.S. Food and Drug Administration review, with a target action date of Oct. 30. President and CEO Jacqueline Shea

Inovio Pharmaceuticals (NASDAQ:INO) is approaching an October 30 PDUFA date for INO-3107, its lead DNA medicine candidate for recurrent respiratory papillomatosis, or RRP, President and CEO Jacky Shea said during a Cantor Fitzgerald fireside chat. Shea described Inovio as a clinical-stage company d

INO-3107 advances toward October FDA decision as company extends cash runway through early 2027.

Inovio Pharmaceuticals (NASDAQ:INO) said the U.S. Food and Drug Administration has completed several key steps in its review of the company’s biologics license application for INO-3107, an investigational treatment for recurrent respiratory papillomatosis, or RRP, while the company continues prepara

Inovio Pharmaceuticals (NASDAQ:INO) shareholders approved all proposals presented at the company’s 2026 annual meeting, including the election of eight directors and the ratification of Ernst & Young LLP as the company’s independent registered public accounting firm for the year ending Dec. 31,

Inovio (INO) Q1 2026 Earnings Call Transcript

Significant news coverage and COVID-19 flashbacks have driven investors into biotech stocks over the past week.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) shares are tumbling Thursday after the company announced the pricing of a proposed public offering.

Inovio (INO) Q4 2025 Earnings Call Transcript

Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are trading higher on Friday morning after the company reported fourth-quarter results.